

**Contact:**

Lee Richardson  
VP Business Development  
919-653-5527  
ParagonDx, LLC  
133 Southcenter Court, Suite 200  
Morrisville, NC 27560  
[press@ParagonDx.com](mailto:press@ParagonDx.com)

FOR IMMEDIATE RELEASE

**ParagonDx to Provide Rapid Genetic Testing to CED's Tech 07 Conference Attendees**

*The company's innovative science and testing kits  
to demonstrate rapid genetic testing results.*

Morrisville, North Carolina – October 11, 2007 – ParagonDx, a recent spin out from Gentris Corporation, will be providing genetic testing of attendees of the Council for Entrepreneurial Development Tech 07 conference. This will be the first time any company in the molecular or pharmacogenomic diagnostic space will be demonstrating the ability to do testing like this in a conference environment.

The purpose of the screening will be to give individuals insight into their sensitivity to certain classes of medications, including warfarin (e.g. Coumadin). This will show the speed of the company's science and testing kits by delivering genetic testing results in hours rather than 7-10 days, which is the current industry norm.

“Our vision from the beginning was to develop diagnostic kits that provide physicians the best and most accurate information to aid their decision making,” stated ParagonDx CEO Michael Murphy. “This demonstration proves we can deliver critical information in hours rather than days, certainly in the time frame similar to other tests ordered by physicians.”

There will be a limited number of tests available during the conference, between 25-75 total, to the attendee population. Attendees will be counseled and be required to sign consent forms. The test has an approximate \$500 value if ordered by a physician.

###

**About ParagonDx**

ParagonDx, located in Morrisville, NC, is a leading provider of applied molecular diagnostic products. Initially a pioneer in the field of pharmacogenomics, ParagonDx has broadened its expertise into molecular diagnostic products. ParagonDx develops and markets reference controls for laboratory quality control and diagnostic kits that bring the promise of personalized medicine to physicians and patients. ParagonDx was the first company to bring FDA-cleared human genomic reference controls to the market. These products are intended to enhance patient safety, improve patients' response to therapy and help realize the promise of personalized medicine. For additional information, please visit [www.ParagonDx.com](http://www.ParagonDx.com).